We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Custom Optimization of Cell Culture Media for Production of Viral Vaccines
Whitepaper

Custom Optimization of Cell Culture Media for Production of Viral Vaccines

Custom Optimization of Cell Culture Media for Production of Viral Vaccines
Whitepaper

Custom Optimization of Cell Culture Media for Production of Viral Vaccines

Vivalis, a Nantes, France-based biotechnology company,has developed EB66®, a novel cell line derived from duck embryonic stem cells for the cell culture production of viral vaccines. The cell line circumvents the quality and quantity control issues associated with traditional chicken egg andprimary chicken embryo fibroblasts, while eliminating the risk of contamination and the costs associated with serum for growing the fibroblasts. As a result, EB66 cells have become a superior industry alternative for the safe, cost effective manufacturing of viral vaccines. Vivalis offers research and commercial licenses for this cell line to pharmaceutical and biotechnology companies for the production of prophylactic and therapeutic vaccines.

Advertisement